OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed this Form 6-K on February 13, 2026. The filing announces the pricing of an underwritten public offering of ordinary shares. The company is headquartered in London, United Kingdom.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics regarding the offering include:
- Shares Offered: 10,815,000 ordinary shares.
- Offering Price: $1.85 per ordinary share.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 1,622,250 shares.
- Gross Proceeds (Base): Approximately $20 million.
- Gross Proceeds (Full Exercise): Approximately $23 million if the over-allotment option is fully exercised.
- Use of Proceeds: Clinical development of product candidates, general corporate purposes, and working capital.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transaction announcement, not a periodic financial report.
Material Changes
The primary material change is the increase in the company's capital base through the issuance of new equity. There is no prior comparable period data provided in this specific filing to assess operational changes.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds primarily to advance the clinical development of its product candidates. The filing notes that the announcement is furnished as Exhibit 99.1 and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability exposure for the specific announcement text. No specific risks or contingencies are detailed within the body of this Form 6-K summary.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and offering expenses.
- Confirm whether the underwriters exercised the 30-day over-allotment option for the additional 1,622,250 shares.
- Review the attached Exhibit 99.1 (News Announcement) for detailed terms of the underwriting agreement.
- Check subsequent filings for updates on the specific allocation of funds to clinical trials.